Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
FAIL · Does not pass the screen
20.45 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 12:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price20.45 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.24)
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 20.45 against the desk's fair-value range, base estimate 40.90, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.24, read 2026-10-24
Ethical does not pass the values gate
Price20.45 USD
Fair value40.90
Ethical score70.0/100
Our investment reviews on this name
2026-10-21Read Markdown18.70+9.4% to today Distribution gives way to Markdown after a 26% slide in 10 weeks
2026-08-15Read Distribution25.30-19.2% to today ✓Markdown gives way to Distribution after a 6% slide in 6 weeks
2026-07-02Read Markdown26.99-24.2% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Tyra Biosciences, Inc. holds its Markdown at $20.45. Consolidating, no directional conviction, held for 12 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 12 days
Price at the screen
$20.45
Valuation
N/A trailing · -7.44 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.75
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.06%
Below 33%
Interest-bearing debt is just 2.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
63.20%
Below 33%
Interest-bearing cash and securities are 63.2% of assets, above the one-third limit.
Fail
Receivables
27.38%
Below 49%
Money owed to the company is 27.4% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Tyra Biosciences,'s business is fine, but its cash and interest-bearing securities are about 63% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TYRA's ethical verdict changes
Today TYRA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +144% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical Biotech Lacks Numbers For Any Call
A lab team tweaking molecules to hit rare FGFR targets sounds clever until the accounts stay blank. Tyra sits at a thirty two dollar share price against an internal value near fifty three, yet carries a forward multiple of minus eleven times, zero profit margin and return on equity of minus thirty seven percent. With no usable financial ratios supplied, the ethical screen simply returns insufficient data and blocks any further view.
That absence matters more than the twelve analysts who still call it a strong buy with a fifty four dollar median target. Clinical stage platforms often burn cash for years, and without the usual ratios there is no way to judge whether the cash runway or governance meets even basic standards. The opportunity rating stays at none for this reason alone.
Risk therefore sits in the unknown itself, from hidden dilution to sudden trial setbacks that hit every early biotech. The market may be optimistic, but missing numbers leave the story untestable. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TYRA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markdown$20.45-0.7%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$20.60+10.2%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown · changed$18.70-6.2%Entry 8
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51.
2026-10-14Distribution$19.94-22.5%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 22.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51.
2026-10-02Distribution$25.73-1.5%Entry 6
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51.
2026-09-15Distribution$26.13+3.3%Entry 5
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51.
2026-07-18Markdown$26.99+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (11 analysts) rates it strong buy, with a mean price target of $51.
2026-07-03Markdown$26.99+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$26.99Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
